SLC5A2 and type 2 diabetes mellitus: Recent studies provided evidence that SGLT2-i use could be effective also on Non- Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) in patients with T2DM by reducing liver fat accumulation [33,34].